Miles Andrews
Miles Andrews
Senior Research Fellow, Monash University
Verified email at
Cited by
Cited by
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ...
Science 359 (6371), 97-103, 2018
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
SC Wei, JH Levine, AP Cogdill, Y Zhao, NAAS Anang, MC Andrews, ...
Cell 170 (6), 1120-1133. e17, 2017
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ...
Nature medicine 24 (11), 1649-1654, 2018
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ...
Science 374 (6575), 1632-1640, 2021
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
SC Wei, NAAS Anang, R Sharma, MC Andrews, A Reuben, JH Levine, ...
Proceedings of the National Academy of Sciences 116 (45), 22699-22709, 2019
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised …
RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ...
The Lancet Oncology 19 (2), 181-193, 2018
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ...
Nature medicine 27 (8), 1432-1441, 2021
Hallmarks of response to immune checkpoint blockade
AP Cogdill, MC Andrews, JA Wargo
British journal of cancer 117 (1), 1-7, 2017
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ...
The Lancet Oncology 20 (7), e378-e389, 2019
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ...
Cell research 29 (10), 846-861, 2019
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells
LJ Vella, A Pasam, N Dimopoulos, M Andrews, A Knights, AL Puaux, ...
Cancer immunology research 2 (4), 351-360, 2014
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, ...
British Journal of Cancer 114 (10), 1084-1089, 2016
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
S Parakh, JJ Park, S Mendis, R Rai, W Xu, S Lo, M Drummond, C Rowe, ...
British journal of cancer 116 (12), 1558-1563, 2017
The nitric oxide system in glucocorticoid-induced hypertension
JA Whitworth, CG Schyvens, Y Zhang, MC Andrews, GJ Mangos, JJ Kelly
Journal of hypertension 20 (6), 1035-1043, 2002
Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat
Y Zhang, MMK Chan, MC Andrews, TA Mori, KD Croft, KUS McKenzie, ...
American Journal of Hypertension 18 (7), 910-916, 2005
The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression
L Huang, S Malu, JA McKenzie, MC Andrews, AH Talukder, T Tieu, ...
Clinical Cancer Research 24 (14), 3366-3376, 2018
The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors
CN Spencer, V Gopalakrishnan, J McQuade, MC Andrews, B Helmink, ...
Cancer Research 79 (13_Supplement), 2838-2838, 2019
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
MP Smith, EJ Rowling, Z Miskolczi, J Ferguson, L Spoerri, NK Haass, ...
EMBO molecular medicine 9 (8), 1011-1029, 2017
Human perforin mutations and susceptibility to multiple primary cancers
JA Trapani, KYT Thia, M Andrews, ID Davis, C Gedye, P Parente, ...
Oncoimmunology 2 (4), e24185, 2013
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
CP Vellano, MG White, MC Andrews, M Chelvanambi, RG Witt, ...
Nature 606 (7915), 797-803, 2022
The system can't perform the operation now. Try again later.
Articles 1–20